Navidea forms Macrophage Therapeutics business unit to explore Therapeutic applications of Manocept
The Manocept platform serves as the molecular backbone of Navidea’s FDA-approved, activated macrophage-targeting agent, Lymphoseek (technetium Tc 99m tilmanocept) injection. Preclinical data being developed by the Company using
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.